Evidence map›Paper›PMID 36422293›Full record

ReviewMetabolites2022

Natural Products Targeting Hsp90 for a Concurrent Strategy in Glioblastoma and Neurodegeneration.

Sarmistha Mitra, Raju Dash, Yeasmin Akter Munni, Nusrat Jahan Selsi, Nasrin Akter, Md Nazim Uddin, Kishor Mazumder, Il Soo Moon

Open access · goldAbstract readReview
In one paragraph

Review in Metabolites, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Sarmistha MitraDepartment of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea.
Raju DashDepartment of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea.ORCID 0000-0003-4128-5308
Yeasmin Akter MunniDepartment of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea.ORCID 0000-0001-5232-7214
Nusrat Jahan SelsiProduct Development Department, Popular Pharmaceuticals Ltd., Dhaka 1207, Bangladesh.
Nasrin AkterDepartment of Clinical Pharmacy and Molecular Pharmacology, East West University Bangladesh, Dhaka 1212, Bangladesh.
Md Nazim UddinDepartment of Pharmacy, Southern University Bangladesh, Chittagong 4000, Bangladesh.
Kishor MazumderDepartment of Pharmacy, Jashore University of Science and Technology, Jashore 7408, Bangladesh.ORCID 0000-0002-8711-7409
Il Soo MoonDepartment of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea.ORCID 0000-0002-1608-016X
Dongguk University · KREast West University · BDSouthern University · BDUNSW Sydney · AU

Funding

National Research Foundation of Korea NRF-2021R1A2C1008564
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is one of the most common aggressive, resistant, and invasive primary brain tumors that share neurodegenerative actions, resembling many neurodegenerative diseases. Although multiple conventional approaches, including chemoradiation, are more frequent in GBM therapy, these approaches are ineffective in extending the mean survival rate and are associated with various side effects, including neurodegeneration. This review proposes an alternative strategy for managing GBM and neurodegeneration by targeting heat shock protein 90 (Hsp90). Hsp90 is a well-known molecular chaperone that plays essential roles in maintaining and stabilizing protein folding to degradation in protein homeostasis and modulates signaling in cancer and neurodegeneration by regulating many client protein substrates. The therapeutic benefits of Hsp90 inhibition are well-known for several malignancies, and recent evidence highlights that Hsp90 inhibitors potentially inhibit the aggressiveness of GBM, increasing the sensitivity of conventional treatment and providing neuroprotection in various neurodegenerative diseases. Herein, the overview of Hsp90 modulation in GBM and neurodegeneration progress has been discussed with a summary of recent outcomes on Hsp90 inhibition in various GBM models and neurodegeneration. Particular emphasis is also given to natural Hsp90 inhibitors that have been evidenced to show dual protection in both GBM and neurodegeneration.

Indexed as

chemosensitivityglioblastomaHsp90neurodegenerations

Identifiers

PMID36422293
PMCPMC9697676
OpenAlexW4309705237

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.